The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
Open accessAbstract
BACKGROUND: Previous trials have shown that the use of statins to lower cholesterol reduces the risk of cardiovascular events among persons without cardiovascular disease. Those trials have involved persons with elevated lipid levels or inflammatory markers and involved mainly white persons. It is unclear whether the benefits of statins can be extended to an intermediate-risk, ethnically diverse population without cardiovascular disease. METHODS: In one comparison from a 2-by-2 factorial trial, we randomly assigned 12,705 participants in 21 countries who did not have cardiovascular disease and were at intermediate risk to receive rosuvastatin at a dose of 10 mg per day or placebo. The first coprimary outcome was the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, and the second coprimary outcome additionally included revascularization, heart failure, and resuscitated cardiac arrest. The median follow-up was 5.6 years. RESULTS: The overall mean low-density lipoprotein cholesterol level was 26.5% lower in the rosuvastatin group than in the placebo group. The first coprimary outcome occurred in 235 participants (3.7%) in the rosuvastatin group and in 304 participants (4.8%) in the placebo group (hazard ratio, 0.76; 95% confidence interval [CI], 0.64 to 0.91; P=0.002). The results for the second coprimary outcome were consistent with the results for the first (occurring in 277 participants [4.4%] in the rosuvastatin group and in 363 participants [5.7%] in the placebo group; hazard ratio, 0.75; 95% CI, 0.64 to 0.88; P<0.001). The results were also consistent in subgroups defined according to cardiovascular risk at baseline, lipid level, C-reactive protein level, blood pressure, and race or ethnic group. In the rosuvastatin group, there was no excess of diabetes or cancers, but there was an excess of cataract surgery (in 3.8% of the participants, vs. 3.1% in the placebo group; P=0.02) and muscle symptoms (in 5.8% of the participants, vs. 4.7% in the placebo group; P=0.005). CONCLUSIONS: Treatment with rosuvastatin at a dose of 10 mg per day resulted in a significantly lower risk of cardiovascular events than placebo in an intermediate-risk, ethnically diverse population without cardiovascular disease. (Funded by the Canadian Institutes of Health Research and AstraZeneca; HOPE-3 ClinicalTrials.gov number, NCT00468923.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“First, there are three large, randomized trials of statin versus placebo where specific cognitive tests were performed, and no differences were seen between statin and placebo (166-169).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [169]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“First, there are three large, randomized trials of statin versus placebo where specific cognitive tests were performed, and no differences were seen between statin and placebo (160–163).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [163]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The Heart Outcomes Prevention Evaluation 3 (HOPE-3), published in 2016, showed that low-dose statin therapy reduced the composite cardiovascular outcome by 24% but had no significant effect on mortality.19”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [19]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The effectiveness of statins for preventing the first occurrence and recurrence of stroke in Japanese populations was confirmed in a sub-analysis of the MEGA study620, 621) and in the JELIS study622).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [621]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Self-citationForouzanfar, M. H., Afshin, A., Alexander, L. T., Anderson, H. R., Bhutta, Z. A., Biryukov, S., Brauer, M., Burnett, R., Cercy, K., Charlson, F. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31679-8 · Cited by 7,698
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
O'Donnell, M. J., Xavier, D., Liu, L., Zhang, H., Chin, S. L., Rao-Melacini, P., Rangarajan, S., Islam, S., Pais, P., McQueen, M. J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60834-3 · Cited by 3,448
Self-citationCollaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Forouzanfar, M. H., Alexander, L., Anderson, H. R., Bachman, V. F., Biryukov, S., Brauer, M., Burnett, R., Casey, D., Coates, M. M., Cohen, A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00128-2 · Cited by 2,701
Semiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Research works printed but not linked: 1
- Sackett DL, 2000, CMAJ, 162, 1311
Cited by
Sorted by citations
Items 201–300 of 847
Cardiovascular Risk Assessment
Pletcher, M. J., & Moran, A. E. (2017) · Medical Clinics of North America · doi:10.1016/j.mcna.2017.03.002 · Cited by 42
Jun, J. E., Cho, I.-J., Han, K., Jeong, I., Ahn, K. J., Chung, H. Y., & Hwang, Y. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.01.030 · Cited by 35
2022 Taiwan lipid guidelines for primary prevention
Huang, P., Lu, Y., Tsai, Y., Wu, Y., Li, H., Chang, H.-Y., Wu, C., Yang, C., Tarng, D., Huang, C., et al. (2022) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2022.05.010 · Cited by 37
Khraishah, H., Daher, R., Garelnabi, M., Karere, G. M., & Welty, F. K. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319370 · Cited by 37
McMahon, G., Creaven, A., & Gallagher, S. M. (2019) · Psychophysiology · doi:10.1111/psyp.13496 · Cited by 34
Loneliness and Social Isolation: Determinants of Cardiovascular Outcomes
Sharma, T., Padala, P. R., & Mehta, J. L. (2021) · Current Cardiology Reviews · doi:10.2174/1573403x17666210129101845 · Cited by 36
Lepor, N. E., Sun, J., Cantón, G., Contreras, L., Hippe, D. S., Isquith, D. A., Balu, N., Kedan, I., Simonini, A. A., Yuan, C., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.05.008 · Cited by 34
Metabolic Syndrome: An Evolving Clinical Construct
Vassallo, P., Driver, S. L., & Stone, N. J. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.07.012 · Cited by 40
Arıkan, İ., Metintaş, S., Kalyoncu, C., & Yıldız, Z. (2009) · PubMed · Cited by 39
Variations in time to benefit among clinical trials of cholesterol-lowering drugs
Barter, P. J., & Waters, D. D. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.04.006 · Cited by 33
Lu, A., Duan, P., Xie, J., Gao, H., Chen, M., Gong, Y. L., Li, J., & Xu, H. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175299 · Cited by 37
Berberine and health outcomes: an overview of systematic reviews
Shi, L.-J., Wang, W., Jing, C., Hu, J. Y., & Liao, X. (2025) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-025-04872-4 · Cited by 38
Long-term moderately elevated LDL-cholesterol and blood pressure and risk of coronary heart disease
Ueda, P., Gulayin, P., & Danaei, G. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200017 · Cited by 32
Cumulative burden of lipid profiles predict future incidence of ischaemic stroke and residual risk
Dai, L., Xu, J., Zhang, Y., Wang, A., Chen, Z., Mo, J., Li, H., Meng, X., Wu, S., & Wang, Y. (2021) · Stroke and Vascular Neurology · doi:10.1136/svn-2020-000726 · Cited by 33
Drug Therapy of Dyslipidemia in the Elderly
Yandrapalli, S., Gupta, S., Andries, G., Cooper, H. A., & Aronow, W. S. (2019) · Drugs & Aging · doi:10.1007/s40266-018-00632-x · Cited by 31
Clinical relevance for lowering C-reactive protein with statins
Arévalo‐Lorido, J. C. (2016) · Annals of Medicine · doi:10.1080/07853890.2016.1197413 · Cited by 33
Impact of the Gut Microbiota on Atorvastatin Mediated Effects on Blood Lipids
Zimmermann, F., Roessler, J., Schmidt, D., Jasina, A., Schumann, P., Gast, M., Poller, W. C., Leistner, D. M., Giral, H., Kränkel, N., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051596 · Cited by 30
Hsu, H., Lin, C., Lee, Y.-S., Wu, T., & Chien, K. (2020) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01567-1 · Cited by 30
Mancini, G. B. J., Ryomoto, A., Yeoh, E., Brunham, L. R., & Hegele, R. A. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad539 · Cited by 28
New Insights Into the Treatment of Hyperlipidemia: Pharmacological Updates and Emerging Treatments
Abbasi, S., Khan, A. A., & Choudhry, M. W. (2024) · Cureus · doi:10.7759/cureus.63078 · Cited by 35
Identifying Causes for Excess Mortality in Patients With Diabetes: Closer but Not There Yet
Yu, O. H. Y., & Suissa, S. (2016) · Diabetes Care · doi:10.2337/dci16-0026 · Cited by 28
The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis
Garshick, M. S., & Underberg, J. A. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0685-7 · Cited by 28
A phenome-wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR
Safarova, M. S., Satterfield, B. A., Fan, X., Austin, E. E., Ye, Z., Bastarache, L. A., Zheng, N. S., Ritchie, M. D., Borthwick, K. M., Williams, M. S., et al. (2019) · npj Genomic Medicine · doi:10.1038/s41525-019-0078-7 · Cited by 29
Ruszkowski, P., Masajtis‐Zagajewska, A., & Nowicki, M. P. (2019) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320319868890 · Cited by 28
Statin Therapy in Very Old Patients: Lights and Shadows
Cobos-Palacios, L., Sanz‐Cánovas, J., Muñoz-Úbeda, M., Lopez-Carmona, M. D., Perez-Belmonte, L. M., Sampalo, A. L., Gómez-Huelgas, R., & Bernal-López, M. R. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.779044 · Cited by 28
Role of Statin Drugs for Polycystic Ovary Syndrome.
Cassidy-Vu, L., Joe, E., & Kirk, J. K. (2016) · Europe PMC (PubMed Central) · Cited by 28
Bernhardt, J. A., Zorowitz, R. D., Becker, K. J., Keller, E., Saposnik, G., Strbian, D., Dichgans, M., Woo, D., Reeves, M. J., Thrift, A. G., et al. (2018) · Stroke · doi:10.1161/strokeaha.118.021380 · Cited by 27
Sivashanmugarajah, A. S., Fulcher, J., SULLIVAN, D. R., Elam, M. B., Jenkins, A. J., & KEECH, A. C. (2019) · Internal Medicine Journal · doi:10.1111/imj.14429 · Cited by 26
Hormone Replacement Therapy After Breast Cancer
Bluming, A. Z. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000595 · Cited by 28
Wang, K.-L., Giugliano, R. P., Goto, S., Chiu, C.-C., Lin, C.-Y., Lai, E., & Chiang, C. (2016) · Heart Rhythm · doi:10.1016/j.hrthm.2016.09.010 · Cited by 27
The heart of Africa: succeeding against the odds
Sliwa, K. S. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31660-9 · Cited by 27
Self-citationIrwin, J. C., Khalesi, S., Fenning, A. S., & Vella, R. K. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.09.013 · Cited by 27
Perioperative Rosuvastatin in Cardiac Surgery
Elgendy, I. Y., Mahmoud, A. N., & Bavry, A. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1608082 · Cited by 28
Landscape of Statin as a Cornerstone in Atherosclerotic Cardiovascular Disease
Yang, C., Wu, Y., Qian, J., & Li, J. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2412373 · Cited by 27
Update in the treatment of extracranial atherosclerotic disease for stroke prevention
Zhu, Z., & Yu, W. (2019) · Stroke and Vascular Neurology · doi:10.1136/svn-2019-000261 · Cited by 26
Bosch, J., Lonn, E., Dagenais, G. R., Gao, P., López-Jaramillo, P. A., Zhu, J., Pais, P. S., Avezum, Á., Sliwa, K. S., Chazova, I. E., et al. (2021) · Stroke · doi:10.1161/strokeaha.120.030790 · Cited by 28
Self-citationMa, W., Pan, Q., Pan, D., Xu, T., Zhu, H., & Li, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.713007 · Cited by 26
Inclisiran: How Widely and When Should We Use It?
Pirillo, A., & Catapano, A. L. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01056-0 · Cited by 27
Predictors of carotid plaque progression over a 4-year follow-up in the Reykjavik REFINE-study
Sturlaugsdottir, R., Aspelund, T., Björnsdóttir, G., Sigurdsson, S. O., Þórsson, B., Eiríksdóttir, G., & Gudnason, V. G. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.12.005 · Cited by 26
2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance
Chien, S.-C., Chen, P.-S., Huang, Y., Tang, S., Li, Y.-H., & Yeh, H. (2018) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.11.017 · Cited by 26
Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease
McClintick, D. J., O’Donoghue, M. L., Ferrari, G. M. D., Ferreira, J., Ran, X., Im, K., López, J. A. G., Elliott‐Davey, M., Wang, B., Monsalvo, M. L., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.11.029 · Cited by 25
Haghikia, A., & Landmesser, U. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.013 · Cited by 25
Coca, A., Kreutz, R. H., Manolis, A. J., & Mancia, G. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002464 · Cited by 25
Dyslipidemia: A Narrative Review on Pharmacotherapy
de Oliveira, L. D., de Assis, A. C. R., Giraldez, V. Z. R., Scudeler, T. L., & Soares, P. R. (2024) · Pharmaceuticals · doi:10.3390/ph17030289 · Cited by 26
Buonpane, A., Trimarchi, G., Ciardetti, M., Coceani, M. A., Alagna, G., Benedetti, G., Berti, S. L., Andò, G., Burzotta, F., & Caterina, A. R. D. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13195791 · Cited by 27
Zuniga, K. B., Graff, R. E., Feiger, D. B., Meng, M. V., Porten, S. P., & Kenfield, S. A. (2019) · Bladder Cancer · doi:10.3233/blc-190249 · Cited by 24
Cheng, Y., Qiao, L., Jiang, Z., Dong, X., Feng, H., Gui, Q., Lu, Y., & Liang, Y. (2020) · PubMed Central · Cited by 25
Prediabetes in Colombia: Expert Consensus
López-Jaramillo, P. A., Calderón, C., Castillo, J., Escobar, I. D., Enrique Melgarejo, R., & Parra, G. A. (2017) · Colombia medica · doi:10.25100/cm.v48i4.3662 · Cited by 30
Self-citationStatin therapy is not warranted for a person with high LDL-cholesterol on a low-carbohydrate diet
Diamond, D. M., Bikman, B. T., & Mason, P. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000764 · Cited by 27
Lecis, D., Prandi, F. R., Barone, L., Belli, M., Sergi, D., Longo, S., Muscoli, S., Romeo, F., Federici, M., Lerakis, S., et al. (2023) · Biomolecules · doi:10.3390/biom13121695 · Cited by 23
Best Treatment Strategies With Statins to Maximize the Cardiometabolic Benefits
Cho, K. I., Sakuma, I., Sohn, I. S., Hayashi, T., Shimada, K., & Koh, K. K. (2018) · Circulation Journal · doi:10.1253/circj.cj-17-1445 · Cited by 23
Schwalm, J.-D. R., McCready, T., Lamelas, P. M., Musa, H., López-Jaramillo, P. A., Yusoff, K., McKee, M., Camacho, P. A., López-López, J., Majid, F. A., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.06.004 · Cited by 23
Self-citationStatins and risk of cataracts: A systematic review and meta‐analysis of observational studies
Alves, C., Mendes, D., & Marques, F. B. (2018) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12480 · Cited by 27
Kostis, J. B., Giakoumis, M., Zinonos, S., Cabrera, J., & Kostis, W. J. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.01.020 · Cited by 23
Pleiotropic Benefits of Statins in Cardiovascular Diseases
Wasim, R., Ansari, T. M., Ahsan, F., Siddiqui, M. H., Singh, A., Shariq, M., & Parveen, S. (2022) · Drug Research · doi:10.1055/a-1873-1978 · Cited by 25
Ennezat, P. V., Guerbaaï, R.-A., Maréchaux, S., Jemtel, T. H. L., & François, P. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001345 · Cited by 24
New Therapeutic Approaches to the Treatment of Dyslipidemia 2: LDL-C and Lp(a)
Kim, K. A., & Park, H. (2023) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2023.12.1.37 · Cited by 23
Bae, S., Ahn, J. B., Joseph, C., Whisler, R., Schnitzler, M. A., Lentine, K. L., KADOSH, B. S., Segev, D. L., & McAdams‐DeMarco, M. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000112 · Cited by 23
Dobrzynski, J. M., Kostis, J. B., Sargsyan, D., Zinonos, S., & Kostis, W. J. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.02.002 · Cited by 23
Control y tratamiento de la hipertensión arterial: Programa 20-20
Gómez, J. F., Camacho, P. A., López-López, J., & López-Jaramillo, P. A. (2019) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2018.06.008 · Cited by 23
Self-citationAre large simple trials for dementia prevention possible?
Whiteley, W. N., Anand, S. S., Bangdiwala, S. I., Bosch, J., Canavan, M. D., Chertkow, H. M., Gerstein, H. C., Gorelick, P. B., O'Donnell, M. J., Paré, G., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz152 · Cited by 24
Self-citationLin, H. C., Lin, J., Tsai, W. C., Lu, C., Chang, W. N., Huang, C. C., Wang, H. C., Kung, C. T., Su, C. M., Su, Y., et al. (2019) · QJM · doi:10.1093/qjmed/hcz189 · Cited by 22
Morales, A., Coca, A., Olsen, M. H., Sanchez, R. A., Sebba-Barroso, W. K., KONES, R. J., Bertoméu, V., Sobrino, J., Alcocer, L. A., Piñeiro, D., et al. (2017) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2017.03.001 · Cited by 22
Self-citationStatins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter?
Rossini, E., Biscetti, F., Rando, M. M., Nardella, E., Cecchini, A. L., Nicolazzi, M. A., Covino, M., Gasbarrini, A., Massetti, M., & Flex, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169326 · Cited by 25
Park, C. S., Yang, H., Han, K., Lee, H., Kang, J., Han, J., Park, K. W., Kang, H., Koo, B., & Kim, H.-S. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.05.003 · Cited by 23
Albuquerque, E. L., Fulco, U. L., Caetano, E. W. S., & Freire, V. N. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108774956.011 · Cited by 21
Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype
Sanin, V., Pfetsch, V., & Köenig, W. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0869-3 · Cited by 24
Joseph, P. G., Lonn, E., Bosch, J., López-Jaramillo, P. A., Zhu, J., Keltai, M., Dans, A., Reid, C. M., Khunti, K. K., Toff, W. D., et al. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.09.026 · Cited by 22
Self-citationMore HOPE for Prevention with Statins
Cushman, W. C., & Goff, D. C. (2016) · New England Journal of Medicine · doi:10.1056/nejme1603504 · Cited by 22
Statins and non-alcoholic fatty liver disease: A concise review
Pereira, E. N. G. D. S., Franco, R. L. C., dos Santos, R. D. C., & Daliry, A. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117805 · Cited by 21
Refining Statin Prescribing in Lower-Risk Individuals
Pender, A., Lloyd‐Jones, D. M., Stone, N. J., & Greenland, P. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.07.753 · Cited by 21
Fixed-Dose Combination (Polypill) for Cardiovascular Disease Prevention: A Meta-Analysis
Abushouk, A. I., Sayed, A., Munir, M., Ghanem, E., Abdelfattah, O., Michos, E. D., Mentias, A. G., Kapadia, S. R., & Nissen, S. E. (2022) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2022.03.027 · Cited by 22
Primary prevention statin therapy in older adults
Nanna, M. G., Abdullah, A., Mortensen, M. B., & Návar, A. M. (2022) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001003 · Cited by 28
Mostaza, J. M., & Escobar, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13071894 · Cited by 26
Consensus statement on the management of dyslipidaemias in adults
Béliard, S., Bonnet, F., Bouhanick, B., Bruckert, É., Cariou, B., Charrière, S., Durlach, V., Moulin, P., Valéro, R., & Vergès, B. L. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.07.033 · Cited by 21
Richard, P. O., Ahmad, A. E., Bashir, S., Hamilton, R. J., Nam, R. K., Leao, R. R. N., Claudio Jeldres, A., & Kulkarni, G. S. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2016.12.009 · Cited by 21
The pharmacodynamic and clinical trial evidence for statin dose
Dimmitt, S. B., Stampfer, H. G., & Warren, J. B. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13539 · Cited by 21
Li, H., Lin, H., Zhao, H.-Y., Yang, X., Cheng, Y., Shen, P., & Zhan, S. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s158850 · Cited by 21
Spannella, F., Filipponi, A., Giulietti, F., Pentima, C. D., Bordoni, V., & Sarzani, R. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002276 · Cited by 21
Singh, B. M., Lamichhane, H. K., Srivatsa, S. S., Adhikari, P., Kshetri, B. J., Khatiwada, S., & Shrestha, D. B. (2020) · Advances in Preventive Medicine · doi:10.1155/2020/6617905 · Cited by 23
Enabling counterfactual survival analysis with balanced representations
Chapfuwa, P., Assaad, S., Zeng, S., Pencina, M. J., Carin, L., & Henao, R. (2021) · ACM Conference on Health, Inference, and Learning (CHIL) · doi:10.1145/3450439.3451875 · Cited by 23
Risk factors of heart disease in nurses
Koshkaki, S. R., Jahromi, M. S. S., Hojat, M., Nazari, F., & Ragibnejad, M. (2017) · Iranian Journal of Nursing and Midwifery Research · doi:10.4103/1735-9066.212986 · Cited by 21
Chazova, I. E., Михайловна, Ч. Н., Blinova, N. V., Владимировна, А. А., Alekseeva, T. A., Ambatiello, L. G., Balanova, Y. А., Bragina, A. E., Danilov, N. M., Drapkina, O. M., et al. (2024) · Systemic Hypertension · doi:10.38109/2075-082x-2024-4-5-109 · Cited by 23
Self-citationA systematic review of subgroup analyses in randomised clinical trials in cardiovascular disease
Brand, K., Hapfelmeier, A., & Haller, B. (2021) · Clinical Trials · doi:10.1177/1740774520984866 · Cited by 19
Assessment of Atherosclerotic Cardiovascular Disease Risk in Primary Prevention
Rikhi, R. R., & Shapiro, M. D. (2022) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/hcr.0000000000000746 · Cited by 22
A review of polypills for the prevention of atherosclerotic cardiovascular disease
Agnello, F. G., Finocchiaro, S., Laudani, C., Legnazzi, M., Mauro, M. S., Rochira, C., Scalia, L., & Capodanno, D. (2023) · American Heart Journal · doi:10.1016/j.ahj.2023.08.012 · Cited by 21
Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
Franczyk, B., Gluba-Brzózka, A., Jurkiewicz, Ł., Penson, P. E., Banach, M., & Rysz, J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1532501 · Cited by 20
Simon, A., & Dézsi, C. A. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01002-8 · Cited by 20
Guideline No. 422e: Menopause and Cardiovascular Disease
Abramson, B. L., Black, D., Christakis, M. K., Fortier, M. P., & Wolfman, W. (2021) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2021.09.010 · Cited by 20
The year in cardiovascular medicine 2021: dyslipidaemia
Tokgözoğlu, L. S., Orringer, C. E., Ginsberg, H. N., & Catapano, A. L. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab875 · Cited by 22
Bias and Loss to Follow‐Up in Cardiovascular Randomized Trials: A Systematic Review
Fong, L. C. W., Ford, T. J., da Costa, B. R., Jüni, P., & Berry, C. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015361 · Cited by 19
Barrios, V., & Escobar, C. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1925539 · Cited by 19
Zhang, J., Wang, X., Tian, W., Wang, T., Jia, J., Lai, R., Wang, T., Zhang, Z., Song, L., Ju, J., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.936817 · Cited by 20
PCSK9 inhibitors and LDL reduction: pharmacology, clinical implications, and future perspectives
Fitzgerald, G., & Kiernan, T. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1497975 · Cited by 21
Nudy, M. S., Cooper, J., Ghahramani, M., Ruzieh, M., Mandrola, J. M., & Foy, A. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.04.028 · Cited by 19
Melhem, S., Steven, S., Taylor, R., & Al-Mrabeh, A. H. (2021) · Nutrients · doi:10.3390/nu13051465 · Cited by 19
Moreno-Arellano, S., Delgado-de-Mendoza, J., & Santi-Cano, M. J. (2018) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2018.03.012 · Cited by 19
Arsenault, B. J., Perrot, N., & Puri, R. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1110 · Cited by 21
Ericsson, H., Nelander, K., Heijer, M., Kjaer, M., Lindstedt, E., Albayaty, M., Forte, P., Fermer, M. L., & Skrtic, S. (2019) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.756 · Cited by 19
Diabetes and cardiovascular disease in older adults
Bilal, A., & Pratley, R. E. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15259 · Cited by 18
Metadata
- Authors
- Yusuf, S., Bosch, J., Dagenais, G., Zhu, J., Xavier, D., Liu, L., Pais, P., López-Jaramillo, P., Leiter, L. A., Dans, A., Avezum, A., Piegas, L. S., Parkhomenko, A., Keltai, K., Keltai, M., Sliwa, K., Peters, R. J. G., Held, C., Chazova, I., Yusoff, K., Lewis, B. S., Jansky, P., Khunti, K., Toff, W. D., Reid, C. M., Varigos, J., Sanchez-Vallejo, G., McKelvie, R., Pogue, J., Jung, H., Gao, P., Diaz, R., & Lonn, E.
- Affiliations
- St. Michael's Hospital (CA)
- Semmelweis University (HU)
- Uppsala University (SE)
- ORCID
- Yusuf, Salim
- Bosch, Jackie
- Dagenais, Gilles
- Zhu, Jun
- Xavier, Denis
- Liu, Lisheng
- Pais, Prem
- López-Jaramillo, Patricio
- Leiter, Lawrence A.
- Piegas, Leopoldo S.
- Parkhomenko, Alexander
- Keltai, Katalin
- Sliwa, Karen
- Peters, Ron J.G.
- Held, Claes
- Chazova, Irina
- Yusoff, Khalid
- Lewis, Basil S.
- Khunti, Kamlesh
- Toff, William D.
- Reid, Christopher M.
- McKelvie, Robert
- Jung, Hyejung
- Lonn, Eva
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-05-26
- Volume
- 374
- Issue
- 21
- Pages
- 2021-2031
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2313998826
- Cited by
- 848
- References
- 23
- Citations by year
- 2026: 32 · 2025: 52 · 2024: 61 · 2023: 66 · 2022: 84 · 2021: 90 · 2020: 75 · 2019: 109 · 2018: 101 · 2017: 97 · 2016: 78
- FWCI
- 142.16
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-nd)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- eSpace (Curtin University) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Leicester Research Archive (University of Leicester) (submittedVersion, other-oa)
- Funders
- AstraZeneca
- Canadian Institutes of Health Research (IR2-91038))
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- rosuvastatin, statins, cholesterol lowering, intermediate cardiovascular risk, primary prevention, cardiovascular events, LDL cholesterol, ethnic diversity, C-reactive protein, cataract surgery, statin adverse effects, muscle symptoms, diabetes risk, cardiovascular mortality, myocardial infarction, stroke, heart failure, revascularization, cardiac arrest, cardiovascular risk stratification, lipid-lowering therapy
- MeSH terms
- Rosuvastatin Calcium, Aged, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Risk Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
